About Ambit Biosciences
Ambit Biosciences is a Healthcare company based in San Diego (United States) founded in 2000, and was acquired by Daiichi Sankyo in September 2014. Kinase inhibitors for cancer and immune disorders were developed. Ambit Biosciences has raised $162.73 million across 6 funding rounds from investors including Daiichi Sankyo, Orbimed and Gimv. The company has 55 employees. Ambit Biosciences offers products and services including Quizartinib, AC410, CSF1R Program, and CEP-32496. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is AMBIT BIOSCIENCES CORPORATION. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Ambit Biosciences was founded in 2000 in San Diego, United States, focusing on the biotechnology sector. Kinase inhibitors were developed by the company for treating cancer and immune disorders. The lead product, quizartinib, an FLT3 inhibitor, advanced to phase III clinical trials for acute myeloid leukemia. Operations centered on drug discovery and development until the acquisition by Daiichi Sankyo in 2014.
- Headquarters San Diego, United States
- Employees 55
- Stage Acquired
- SectorsHealthcare
- Website ambitbio.com
- Social LinkedIn
- Acquired by Daiichi Sankyo (Sep 2014)
- Legal Name Ambit Biosciences Corporation
- Total Equity Funding$162.73M (USD)
in 6 rounds
- Latest Funding Round$50M (USD), Series E
Nov 2012
- InvestorsDaiichi Sankyo
& 14 more
- Employee Count55
- Acquired byDaiichi Sankyo
(Sep 2014)
Products & Services of Ambit Biosciences
Ambit Biosciences offers a comprehensive portfolio of products and services, including Quizartinib, AC410, CSF1R Program, and CEP-32496.
FLT3 inhibitor for treating acute myeloid leukemia in oncology.
JAK2 inhibitor targeting autoimmune and inflammatory conditions.
CSF1R inhibitor for oncology and inflammatory disease applications.
BRAF kinase inhibitor for cancer therapy development.
Funding Insights of Ambit Biosciences
Ambit Biosciences has successfully raised a total of $162.73M across 6 strategic funding rounds. The most recent funding activity was a Series E round of $50 million completed in November 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $162.73M
- Total Rounds 6
- Last Round Series E — $50M
- First Round $49.3M
(Nov 2007)
- Investors Count 14
All 6 funding rounds of Ambit Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2012 | $50M | Series E | – | Orbimed, Aisling Capital | – |
| Jun 2011 | $30M | Series D | – | Apposite Capital | |
| Oct 2010 | $15M | Series D | – | – | – |
| Apr 2010 | $12M | Series D | – | – | – |
| Jun 2009 | $6.43M | Series D | – | – | – |
| Nov 2007 | $49.3M | Series D | – | – |
15 investors in total: 15 institutional.
Investors in Ambit Biosciences
Ambit Biosciences has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Daiichi Sankyo, Orbimed and Gimv.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Healthcare impact investments are managed by Apposite Capital. | appositecapital.com | London, United Kingdom | ||
Stage-agnostic sector-agnostic VC firm investing in Canada and the US | growthworks.ca | Vancouver, Canada | ||
| medimmuneventures.com | ||||
Life Sciences focused VC firm that does early stage investments in the US | forwardventures.com | San Diego, United States | ||
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
| radiusventures.com | ||||
Corporate-backed venture capital firm focused on the healthcare sector | roche.com/venturefund.htm | |||
Structured debt is provided to life sciences and technology firms. | 2004 | horizontechfinance.com | Farmington, United States |
Investor details for Ambit Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ambit Biosciences
5 dated milestones of Ambit Biosciences across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Ambit Biosciences is founded.
- Funding First funding round of $49.3M.
- Funding Latest funding round, Series E, of $50.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Daiichi Sankyo.
Competitors of Ambit Biosciences
Ambit Biosciences has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Ambit Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ambit Biosciences
Websites that share an audience with Ambit Biosciences (ambitbio.com).
Websites whose visitors overlap most with Ambit Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
nextgensciences.com | nextgensciences.com | 100% | – | ||
| perkinelmer.com | 63% | 164.5K | #258,286 | View details | |
| biocryst.com | 63% | 16.2K | #1,533,322 | View details |
Top companies in Oncology
3 companies that operate in the same segment as Ambit Biosciences (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ambit Biosciences
Complete news archive for Ambit Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ambit Biosciences
Ambit Biosciences was founded in 2000 and raised its 1st funding round 7 years after it was founded.
Ambit Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Ambit Biosciences is a funded company, having raised a total of $162.73M across 6 funding rounds to date. The company's 1st funding round was a Series D of $49.3M, raised on Nov 2007.
Ambit Biosciences has 55 employees.
Ambit Biosciences was founded in 2000 in San Diego, United States, focusing on the biotechnology sector. Kinase inhibitors were developed by the company for treating cancer and immune disorders. The lead product, quizartinib, an FLT3 inhibitor, advanced to phase III clinical trials for acute myeloid leukemia. Operations centered on drug discovery and development until the acquisition by Daiichi Sankyo in 2014.
Ambit Biosciences offers Quizartinib, AC410, CSF1R Program, and CEP-32496.
Ambit Biosciences has 15 investors. Key investors include Daiichi Sankyo, Orbimed, Gimv, Horizon Tech Finance, and Aisling Capital.
Ambit Biosciences operates through Ambit Biosciences Corporation.
Yes. Ambit Biosciences was acquired by Daiichi Sankyo in September 2014.